Interferon is important for anti-viral defense of the host. The E2, NS3/4A, and NS5A proteins of hepatitis C virus (HCV) have recently been reported to confront anti-viral action induced by interferon. However, roles of the individual HCV proteins in anti-interferon action are still not well understood. We have isolated an HCV strain, HCV-K, from a patient with acute hepatitis. Nucleotide sequencing of the entire genomic DNA of HCV-K revealed that the isolate belongs to the genotype 1b, which is generally resistant to interferon therapy. In the present study, we expressed individual HCV-K proteins in mammalian cells and investigated effects of the proteins on interferon signal transduction. The results showed that the core, E1, NS4A, and NS4B proteins suppressed activation of interferon stimulation responsive element (ISRE) and gamma activation sequence (GAS) reporters. These results suggest that multiple HCV proteins have a function in suppression of the anti-viral effect by interferon and may indicate a novel role of E1 and NS4B proteins in interferon antagonism.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers.
PLoS Comput Biol
January 2025
Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Quantification of intrahepatic covalently closed circular DNA (cccDNA) is a key for evaluating an elimination of hepatitis B virus (HBV) in infected patients. However, quantifying cccDNA requires invasive methods such as a liver biopsy, which makes it impractical to access the dynamics of cccDNA in patients. Although HBV RNA and HBV core-related antigens (HBcrAg) have been proposed as surrogate markers for evaluating cccDNA activity, they do not necessarily estimate the amount of cccDNA.
View Article and Find Full Text PDFHepatitis B virus genotypes A1 and A2 have distinct replication phenotypes due to polymorphisms in the HBx gene.
PLoS Pathog
January 2025
Liver Diseases Branch, NIDDK, NIH, Bethesda, Maryland, United States of America.
HBV genotype A has two major subtypes, A1 (commonly in Africa) and A2 (commonly in Europe) with only 4% nucleotide differences. Individuals infected with these two subtypes appear to have different clinical manifestations and virologic features. Whether such a difference results from the virus or host has not been established.
View Article and Find Full Text PDFA yeast-assembled, plasmid-launched reverse genetics system for the murine coronavirus MHV-A59.
J Gen Virol
January 2025
Biochemistry Program, The University of the South, Sewanee, TN, USA.
The murine hepatitis virus (MHV) is an important model system for studying coronavirus (CoV) molecular and cell biology. Despite this, few reagents for MHV are available through repositories such as ATCC or Addgene, potentially limiting the widespread adoption of MHV as a tractable model system. To overcome some challenges inherent in the existing MHV reverse genetics systems, we developed a plasmid-launched transformation-associated recombination (TAR) cloning-based system to assemble the MHV (strain A59; MHV-A59) genome.
View Article and Find Full Text PDFResistance-associated substitutions (RASs) are mutations within the hepatitis C (HCV) genome that may influence the likelihood of achieving a sustained virological response (SVR) with direct acting antiviral (DAA) treatment. Clinicians conduct RAS testing to adapt treatment regimens with the intent of improving the likelihood of cure. The Canadian Network Undertaking against Hepatitis C (CANUHC) prospective cohort consists of chronic HCV patients enrolled between 2015 and 2023 across 17 Canadian sites.
View Article and Find Full Text PDFBaseline FIB-4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV-Related Small HCC.
Cancer Med
January 2025
Department of Gastroenterology, Peking University First Hospital, Beijing, China.
Aims: Exploring fibrosis index-4 (FIB-4)'s predictive value for HBV-related hepatocellular carcinoma (HCC) in assessing recurrence following stereotactic body radiation therapy (SBRT) in patients with HBV-related HCC.
Methods: HBV-related HCC patients who underwent SBRT were retrospectively enrolled from March 2012 to March 2020. Patients were divided into recurrence and non-recurrence groups based on the HCC recurrence situation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!